Citigroup’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-58,529
| Closed | -$174K | – | 7477 |
|
|
2016
Q3 | $174K | Buy |
58,529
+53,968
| +1,183% | +$93.5K | ﹤0.01% | 4765 |
|
|
2016
Q2 | $6K | Sell |
4,561
-35,168
| -89% | -$80.4K | ﹤0.01% | 6748 |
|
|
2016
Q1 | $147K | Buy |
39,729
+8,997
| +29% | +$55.7K | ﹤0.01% | 5370 |
|
|
2015
Q4 | $310K | Sell |
30,732
-5,198
| -14% | -$62.6K | ﹤0.01% | 4328 |
|
|
2015
Q3 | $488K | Buy |
35,930
+27,204
| +312% | +$484K | ﹤0.01% | 3772 |
|
|
2015
Q2 | $166K | Buy |
8,726
+185
| +2% | +$4K | ﹤0.01% | 4588 |
|
|
2015
Q1 | $223K | Sell |
8,541
-3,688
| -30% | -$93.9K | ﹤0.01% | 4433 |
|
|
2014
Q4 | $257K | Buy |
12,229
+10,225
| +510% | +$258K | ﹤0.01% | 4487 |
|
|
2014
Q3 | $67K | Sell |
2,004
-5,388
| -73% | -$167K | ﹤0.01% | 5079 |
|
|
2014
Q2 | $237K | Sell |
7,392
-7,221
| -49% | -$269K | ﹤0.01% | 4006 |
|
|
2014
Q1 | $674K | Sell |
14,613
-1,456
| -9% | -$85.4K | ﹤0.01% | 3210 |
|
|
2013
Q4 | $1.14M | Buy |
16,069
+7,459
| +87% | +$570K | ﹤0.01% | 3063 |
|
|
2013
Q3 | $738K | Buy |
8,610
+5,804
| +207% | +$492K | ﹤0.01% | 3124 |
|
|
2013
Q2 | $178K | Buy |
+2,806
| New | +$149K | ﹤0.01% | 4374 |
|
Citigroup's AEGR Position: Q4 2016 in Review
Citigroup sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 58,529 shares — an estimated $174K sold.
Citigroup first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $1.14M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Citigroup reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Citigroup sold 58,529 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $174K.
- Citigroup first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Citigroup's Aegerion Pharmaceuticals position peaked at $1.14M in Q4 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.